DEF: VolitionRx Seeks Stockholder Approval for Increased Authorized Shares at 2025 Annual Meeting

Sentiment:

Proxy Statement 29 April 2025 4:18 PM

VolitionRx Limited is holding its 2025 Annual Meeting of Stockholders on June 18, 2025, to vote on key proposals including the election of directors and an increase in authorized shares.

Capital raiseThe company seeks to increase the authorized shares of common stock from 175,000,000 to 325,000,000.The additional shares of common stock will be available for issuance by the board of directors for various corporate purposes, including but not limited to, grants under employee stock plans, financings, potential strategic transactions, including mergers, acquisitions, strategic partnerships, joint ventures, divestitures, business combinations, stock splits, stock dividends, as well as other general corporate transactions.The company has approximately $7.5 million of common stock remaining available to be sold from time to time under its Capital On DemandTM Sales Agreement with JonesTrading Institutional Services LLC dated April 22, 2025.On March 24, 2025, the company entered into a securities purchase agreement with the several purchasers, pursuant to which we issued and sold to such purchasers, in a registered direct offering, an aggregate of (i) 2,363,636 shares of our common stock to certain of our directors and executive officers, and certain of our existing stockholders (collectively, the March RDO Insiders) at an offering price of $0.55 per share (the Insider Shares), and (ii) 1,739,087 shares of common stock (the Warrant Investor Shares and, together with the Insider Shares, the March 2025 Shares), together with common stock purchase warrants to purchase up to 1,739,087 shares of common stock (the March 2025 Warrants), at a combined offering price of $0.55 per Warrant Investor Share and accompanying March 2025 Warrant, to certain other existing stockholders of the Company and new investors.The gross proceeds received by the Company for the issuance and sale of the March 2025 Shares and the March 2025 Warrants was $2.3 million, before deducting offering expenses of $0.1 million paid by the Company.

Summary

VolitionRx Limited will hold its Annual Meeting of Stockholders on June 18, 2025, in London.
Stockholders will vote on the election of eight directors, ratification of the independent accounting firm, approval of executive compensation, and an increase in authorized shares of common stock.
The board recommends voting FOR all proposals.
The company seeks to increase the authorized shares of common stock from 175,000,000 to 325,000,000.
As of April 25, 2025, VolitionRx had 100,775,334 shares of common stock issued and outstanding.
The company is taking advantage of SEC rules to furnish proxy materials over the internet.
Broadridge Financial Solutions, Inc. will be paid approximately $9,000 for distribution and tabulation services, and Georgeson, LLC will be paid $10,500 for proxy solicitation services.

Sentiment

Score: 6

Explanation: The document is primarily informational, with a neutral tone. The company is seeking approval for routine matters, but the need for increased authorized shares and past material weaknesses suggest some financial challenges.

Positives

The board of directors is actively engaged in corporate governance and risk oversight.
The company is committed to stockholder engagement and considers stockholder feedback.
The company has adopted a Code of Ethics applicable to directors, officers, and employees.
The company has a Clawback and Forfeiture Policy in place.
The company is taking steps to remediate material weaknesses in internal control over financial reporting.

Negatives

The company has historically had material weaknesses in its internal control over financial reporting.
The company's ability to continue as a going concern is dependent upon its successful transition to commercialization as well as continued capital contributions and financing.

Risks

The outcomes of forward-looking statements are subject to risks, uncertainties, and other factors described in the company's Annual Report on Form 10-K.
Future issuances of shares of common stock could have a dilutive effect on earnings per share, voting power, and percentage stockholdings of current stockholders.
The availability of additional shares of common stock for issuance could, under certain circumstances, discourage or make more difficult any efforts to obtain control of the Company.

Future Outlook

The company aims to give itself greater flexibility in considering and planning for future potential business needs by increasing the number of authorized shares of common stock.

Management Comments

The Companys board of directors unanimously recommends that you vote FOR the election of each of the director nominees named in Proposal 1, and FOR Proposals 2, 3, and 4.

Industry Context

Proxy statements are standard documents for publicly traded companies, providing transparency and enabling shareholders to make informed decisions on key corporate matters. The proposals outlined are typical for an annual meeting.

Comparison to Industry Standards

The structure and content of this proxy statement are consistent with industry standards for publicly traded companies in the United States.
The proposals, including the election of directors, ratification of auditors, and approval of executive compensation, are common items for shareholder voting at annual meetings.
The company's disclosure of related party transactions and corporate governance practices aligns with regulatory requirements and best practices.
The compensation arrangements for named executive officers are comparable to those of similar-sized companies in the biotechnology and diagnostics industries.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Executive Chairman of the board of directors	Dr. Martin Faulkes	NA	July 2, 2024	Dr. Faulkes retired from the Board of VolitionRx and also stepped down as Executive Chairman but continued to be employed by the Company for a three-month period to assist with the transition of the Chairman position among other duties.
Director	Dr. Edward Futcher	NA	July 2, 2024	Dr. Futcher retired from the Board of VolitionRx.
Director	NA	Dr. Ethel Rubin	September 30, 2024	NA
Director	NA	Timothy Still	November 6, 2024	NA

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Increase in Authorized Shares	The company is seeking stockholder approval to increase the number of authorized shares of common stock from 175,000,000 to 325,000,000.	Upon Stockholder Approval and Filing	Provides greater flexibility for future corporate actions, including financings, acquisitions, and stock-based compensation.

Legal Proceedings

There are no material legal proceedings disclosed in this document.

Related Party Transactions

Guy Innes, a member of the board of directors, participated in the February 2023 confidentially marketed public offering, purchasing 234,000 shares for $409,500.
Lagoda Investment Management, L.P., a beneficial owner of more than 5% of the Companys outstanding common stock, participated in the March 2025 registered direct offering through certain of its managed accounts, purchasing an aggregate of 2,000,000 Insider Shares for an aggregate purchase price of $1.1 million and did not receive any March 2025 Warrants.

Stakeholder Impact

Approval of the increase in authorized shares could impact stakeholders by providing the company with greater financial flexibility.
Future issuances of common stock could dilute existing stockholders' ownership.
The company's commitment to corporate governance and ethical conduct aims to protect the interests of all stakeholders.

Next Steps

Stockholders should review the proxy materials and vote on the proposals.
The company will hold its Annual Meeting on June 18, 2025.
The company will file a Form 8-K to report the final voting results.

Key Dates

Date	Description
September 26, 2011	Date of the share exchange agreement with Singapore Volition.
October 6, 2011	Effective date of the share exchange agreement with Singapore Volition.
December 31, 2024	End of the fiscal year for which financial and compensation information is provided.
April 2, 2025	Date the board of directors approved the Second Amendment to the Restated Certificate.
April 22, 2025	Date of the Capital On DemandTM Sales Agreement with JonesTrading Institutional Services LLC.
April 25, 2025	Record date for determining stockholders entitled to notice of and to vote at the Annual Meeting.
May 5, 2025	Approximate date of mailing of Notice of Internet Availability of Proxy Materials.
June 17, 2025	Deadline for submitting proxies via Internet or telephone.
June 18, 2025	Date of the Annual Meeting of Stockholders.
January 5, 2026	Deadline for receipt of stockholder proposals for inclusion in the 2026 proxy statement.
February 19, 2026	Earliest date for stockholders to submit proposals or director nominations for the 2026 annual meeting (outside of proxy statement).
March 21, 2026	Latest date for stockholders to submit proposals or director nominations for the 2026 annual meeting (outside of proxy statement).
April 19, 2026	Deadline for stockholders to provide notice of intent to solicit proxies in support of director nominees other than the company's nominees.

Keywords

proxy statement, annual meeting, stockholders, directors, executive compensation, authorized shares, corporate governance, audit committee, VolitionRx

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.